Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  cabozantinib-s-malate
Find trials that include:  Any drugs shown
Results 1-25 of 26 for your search:
Start Over
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: XL184-309, NCI-2013-02092, NCT01908426
Cabozantinib-S-Malate, Docetaxel, and Prednisone in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9243, NCI-2013-01554, 120204, P11901, 12-C-0204, NCT01683994
Cabozantinib in Treating Patients with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Involvement
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-208, NCI-2011-03519, XL184-IST12, NCT01441947
Cabozantinib-s-Malate in Treating Patients with Advanced Pancreatic Neuroendocrine or Carcinoid Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11-274, NCI-2012-00539, NCT01466036
Cabozantinib-s-malate in Treating Patients with Metastatic or Refractory Solid Tumors and Bone Metastases
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-091, NCI-2012-00991, NCT01588821
Cabozantinib-s-malate in Treating Patients with Non-small Cell Lung Cancer That Is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-097, NCI-2012-01187, NCT01639508
Cabozantinib-S-Malate in Treating Patients with Refractory Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9284, NCI-2012-03124, 09-25-0099, 121088, 130044, P121088, P9284_A07PAMDREVW01, 13-C-0044, NCT01755195
Cabozantinib-S-Malate in Treating Patients with Refractory Thyroid Cancer
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9312, NCI-2013-00554, 2012C0101, OSU 12154, RU241210I, NCT01811212
Cabozantinib-S-Malate as First-Line Therapy in Treating Patients With Radioiodine-Refractory Thyroid Cancer That is Metastatic or Cannot Be Removed By Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 28313, NCI-2014-00171, 818408, UPCC 28313, NCT02041260
Cabozantinib S-malate in Treating Patients with Plexiform Neurofibromas or Neurofibromatosis Type 1
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 and over
Trial IDs: NF Protocol 105 (CABO), NCI-2015-01578, 105, Exelixis: XL184-IST14, F130502005, NCT02101736
Cabozantinib-s-malate in Treating Patients with Previously Treated Non-small Cell Lung Cancer and Brain Metastases
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-182, NCI-2014-01505, PRO14050009, UPCI #13-182, NCT02132598
Cabozantinib-s-malate in Treating Patients with Relapsed Osteosarcoma or Ewing Sarcoma
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 and over
Trial IDs: 9620, NCI-2014-01927, CABONE, NCT02243605
Cabozantinib S-malate with or without Trastuzumab in Treating Patients with Breast Cancer and Brain Metastases
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-359, NCI-2014-02365, NCT02260531
Cabozantinib S-malate in Treating Patients with Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0081, NCI-2014-02607, NCT02302833
Cabozantinib-S-Malate in Treating Patients with Recurrent or Metastatic Endometrial Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9322, NCI-2013-00890, NCT01815151, PHL-086, NCT01935934
Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients with Locally Advanced or Metastatic Kidney Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Any age
Trial IDs: S1500, NCI-2015-01707, NCT02761057
Cabozantinib-S-Malate in Treating Younger Patients with Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 2 to 30
Trial IDs: ADVL1622, NCI-2016-01258, NCT02867592
Cabozantinib-s-malate in Treating Patients with Relapsed or Refractory Multiple Myeloma with Bone Disease
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-005, NCI-2012-01143, NCT01582295
Cabozantinib-S-Malate in Treating Patients with Advanced Solid Tumors and Human Immunodeficiency Virus
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-087, NCI-2013-00740, NCT01822522
Cabozantinib-S-Malate in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-363, NCI-2014-00084, NCT01961765
Cabozantinib-S-Malate and Panitumumab in Treating Patients with Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00049983, NCI-2014-01160, NCT02008383
Cabozantinib-s-malate and Nivolumab with or without Ipilimumab in Treating Patients with Metastatic Genitourinary Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9681, NCI-2014-02379, 150160, P141706, 15-C-0160, NCT02496208
Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 7819, NCI-2012-01898, NCT01703065
Cabozantinib-S-Malate in Treating Patients with Recurrent or Metastatic Merkel Cell Carcinoma
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 13-490, NCI-2014-00941, NCT02036476
Expanded Access of Cabozantinib in Medullary Thyroid Cancer
Status: Not yet active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: XL184-209, NCI-2012-02141, NCT01683110
Start Over